Yuwell Medical Wrist Ambulatory Blood Pressure Monitor Receives Class II Medical Device Registration Certificate

Jiemian··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Yuwell Medical announced that its wrist ambulatory blood pressure monitor has obtained a Class II medical device registration certificate issued by the Jiangsu Medical Products Administration. The product registration certificate number is Su Xie Zhu Zhun 20262071109, valid from July 24, 2026 to July 23, 2031, covering 12 models from WBA10 to WBA61. The product supports single blood pressure measurement, 24-hour ambulatory blood pressure measurement, and nighttime blood pressure monitoring, can record blood pressure data and display trends, and also features monitoring of health parameters such as heart rate, blood oxygen, stress, and sleep. It is used for measuring systolic pressure, diastolic pressure, and pulse rate in adults, with the values provided for clinical reference. The company stated that this is an important achievement of its digital and intelligent strategy centered on health management and wearable devices, which will enrich its wearable product matrix and improve its personal and family health management layout. It also cautioned that future sales are subject to uncertainties due to factors such as industry policies, market demand, and the competitive environment.

Impact on assets 1

Others▲

Theme Impact 1

Related news

United States
▲2

Glaukos iDose TR Hits Primary Goal in Phase 4 Glaucoma Trial

Glaukos Corp. said its iDose TR travoprost intracameral implant met the primary goal of a phase 4 trial in patients with open-angle glaucoma or ocular hypertension. At three months, participants who underwent cataract surgery and received iDose TR saw a mean diurnal intraocular pressure reduction of 11.1 mmHg from baseline, compared with 7.4 mmHg for those who had cataract surgery alone. The iDose TR arm was also superior to cataract surgery alone in secondary responder analyses. No treatment-related adverse events of corneal endothelial cell loss, cystoid macular edema, or serious corneal adverse events were reported. iDose TR is designed to provide a continuous supply of travoprost inside the eye for up to three years.
About megatrends
Aging Population › Vision & Eye Care ▲Technology
GKOS · Technology · Positive iDose TR met the primary endpoint in a Phase 4 glaucoma trial, showing superior intraocular pressure reduction with no serious adverse events.
Read original ↗
Seeking Alpha·1dRead more →
China

Huaxia Eye Hospital appoints Yang Weilai as board secretary; former secretary Cao Naien resigns

Huaxia Eye Hospital announced on October 9 that former board secretary Cao Naien resigned for personal reasons and will no longer hold any position at the company. The company's board of directors held a meeting on October 9, 2026, and decided to appoint Yang Weilai as board secretary, with a term starting from the date of approval by this board meeting until the end of the fourth board's term. In the first half of 2026, Huaxia Eye Hospital achieved revenue of 2.185 billion yuan and net profit attributable to the parent of 292 million yuan.
About megatrends
Aging Population › Hearing / Vision / Dental Talent
Aging Population › Vision & Eye Care Talent
301267.CS · · Neutral Board secretary Cao Naien resigns and Yang Weilai is appointed as replacement; a routine management change with no clear financial driver.
Read original ↗
财中社·2dRead more →
United States
2

Glaukos Reports Three-Year Epioxa Keratoconus Data and RevOpsis Licensing Deal

Glaukos Corporation reported positive three-year extension trial results for its non-invasive keratoconus treatment Epioxa while simultaneously securing an exclusive licensing deal to broaden its retinal disease pipeline. In the GLK-202-03 extension study, 38 study eyes across 35 subjects were followed for up to three years after a single Epioxa treatment with no further medical interventions, and 92% of participant eyes completed the final three-year assessment visit. Treated eyes maintained a 1.9 diopter improvement in maximum corneal curvature from baseline, while 29% of eyes gained two or more lines of best-corrected visual acuity and 20% gained three or more lines, with zero serious adverse events, treatment-related adverse events, or therapy-related discontinuations. Separately, Glaukos announced an exclusive licensing agreement with RevOpsis Therapeutics Inc. to develop and commercialize RO-104, a first-in-class tri-specific biologic targeting neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion, which blocks VEGF-A and VEGF-C while inhibiting Ang-2. The deal grants Glaukos exclusive rights to use the RevMod platform to develop up to four additional retinal biologics, with financial terms not disclosed. Glaukos shares were down 10.76% at $153.65 at the time of publication on Thursday.
About megatrends
Aging Population › Vision & Eye Care Technology
GKOS · Technology · Positive Positive three-year Epioxa keratoconus extension data with durable 1.9 diopter improvement and zero serious adverse events.
GKOS · Demand · Positive Exclusive licensing deal with RevOpsis to develop and commercialize RO-104 and up to four additional retinal biologics, broadening its pipeline.
RevOpsis Therapeutics · Capital · Neutral RevOpsis is the licensor in the exclusive RO-104 deal with Glaukos, but financial terms were not disclosed.
Read original ↗
Benzinga·2dRead more →
SwitzerlandUnited States
▲

Goldman Sachs Upgrades Sonova to Buy, Shares Hit 16-Month High

Goldman Sachs upgraded Sonova Holding to buy from neutral and raised its price target to CHF315 from CHF230, sending the hearing-aid maker's shares to a 16-month high. The stock rose around 0.5% to its highest level since June 11, 2025, outperforming a broader Swiss market that saw the SMI fall about 0.8% on Thursday. Goldman Sachs said Sonova is well positioned to outperform the overall hearing-aid market, citing product innovation, opportunities to gain market share in Asia and improving industry fundamentals. The broker expects the company to deliver around 9% constant-currency revenue growth in the first half of fiscal 2027, well above Visible Alpha consensus of 6.2%, which it sees as a potential catalyst for the shares. Goldman now expects Sonova to reach the upper end of its FY27 guidance, forecasting 7.8% constant-currency revenue growth versus 6.6% consensus, while adjusted EBIT growth including FX is seen at 12.6% versus 6.5% consensus, and it raised FY27-29 revenue estimates by 4%-7% and adjusted EBIT and EPS estimates by 7%-10%. The next major catalyst is Sonova's November 12 first-half FY27 results, where Goldman expects the company's stronger-than-consensus growth to become more visible.
About megatrends
Aging Population › Hearing (aids & cochlear implants) ▲Capital
Aging Population › Hearing / Vision / Dental ▲Capital
SOON.SW · Capital · Positive Goldman Sachs upgraded Sonova to buy and lifted its price target to CHF315 from CHF230, sending shares to a 16-month high
GS · Capital · Positive Goldman Sachs upgraded Sonova to buy and raised its price target, a positive analyst action for the broker's research franchise
Read original ↗
Investing.com·3dRead more →
China
▼5

Guangzheng Eye Hospital Subsidiary Fined RMB 1.0456 Million for Medical Insurance Settlement Violations

Guangzheng Eye Hospital announced after market close on October 8 that its subsidiary Shanghai New Vision Eye Hospital Co., Ltd. received an administrative penalty decision from the Shanghai Municipal Medical Security Bureau. For including medical expenses that did not fall within the payment scope of the medical security fund in its settlements, causing losses to the fund, it was fined RMB 1.0456 million. The announcement showed that the conduct fell under item 6 of Article 38 of the Regulations on the Supervision and Administration of the Use of Medical Security Funds. As of the disclosure date, Guangzheng Eye Hospital and its controlled subsidiaries had accumulated administrative penalties totaling RMB 1.9712 million over the preceding 12 consecutive months, accounting for 10.11% of the company's most recent audited net profit attributable to the parent. All fines have been paid and recorded in current profit or loss. The company said the penalty will affect operating results for 2026, with the final actual impact subject to the annual audit by its accounting firm, but it will not have a material impact on long-term development and does not trigger mandatory delisting for major violations. The subsidiary hospital has completed special rectification as required, including organizing study of the relevant regulations and medical insurance service agreements, assigning dedicated personnel for medical insurance management, improving oversight procedures, and establishing accountability mechanisms.
About megatrends
Aging Population › Vision & Eye Care ▼Regulation
002524.CS · Regulation · Negative Subsidiary fined RMB 1.0456 million for medical insurance settlement violations, with cumulative penalties of RMB 1.9712 million hitting 10.11% of net profit.
上海新视界眼科医院有限公司 · Regulation · Negative Shanghai New Vision Eye Hospital was fined RMB 1.0456 million by the Shanghai Medical Security Bureau for improper medical insurance fund settlements.
Read original ↗
每日经济新闻·3dRead more →
United States

Bausch + Lomb Advances Oral Dry AMD Treatment After FDA Meeting

Bausch + Lomb said it has made progress developing tonabersat, also known as BL1243, an oral treatment for dry age-related macular degeneration, following a meeting with the US FDA. The company said discussions with the agency yielded greater clarity on the clinical development path for BL1243. Bausch + Lomb added that the FDA supported, in principle, its initial study to evaluate the candidate's safety and how it acts in the body. Assuming that study goes well, tonabersat will move into a phase 2 study in individuals with dry AMD but without advanced retinal damage. The clinical program for tonabersat is slated to begin in 2027.
About megatrends
Aging Population › Vision & Eye Care Technology
BLCO · Technology · Positive FDA meeting yields clarity on clinical path for oral dry AMD candidate tonabersat, advancing its development
Read original ↗
Seeking Alpha·4dRead more →